All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your Lymphoma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene and Roche, and supported through educational grants from Bristol Myers Squibb, Ipsen Biopharmaceuticals, Pfizer, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC View funders.
#SOHO2024: Indolent B-cell lymphoma
Bookmark this article
To update you on the exciting content presented at the Society of Hematologic Oncology (SOHO) 2024 Annual Meeting, we have collated our social media coverage. Catch up with our live social media coverage relating to indolent B-cell lymphoma below.
CONGRESS | #SOHO2024 | POSTER
— Lymphoma Hub (@lymphomahub) September 9, 2024
Lorenzo Falchi @MSKCancerCenter presents data from the phase I/II EPCORE NHL-2 trial of fixed-duration epcoritamab + R2 in 1L FL (updated data from Arm 6) and single-agent epcoritamab as maintenance treatment after SOC in FL (first disclosure of Arm… pic.twitter.com/AZm6OAH8OO
CONGRESS | #SOHO2024 | POSTER
— Lymphoma Hub (@lymphomahub) September 9, 2024
Saurabh Dahiya, Stanford University School of Medicine, presents subgroup analysis by bridging therapy from TRANSCEND FL study of liso-cel as 2L therapy in R/R FL. ORR and CR rates were high and consistent across subgroups; median DOR, PFS, and OS… pic.twitter.com/jiiNY9lua8
CONGRESS | POSTER | #SOHO2024 | Stephen Schuster @Penn presented 3-year follow-up updates from a pivotal phase II study of mosenutuzumab in heavily pretreated R/R FL (N=90). Long-lasting remissions were achieved, with 3-year PFS and OS stable and estimated 30-month DOR rate 72.7%… pic.twitter.com/S00booYr00
— Lymphoma Hub (@lymphomahub) September 4, 2024
CONGRESS | #SOHO2024
— Lymphoma Hub (@lymphomahub) September 10, 2024
Izidore Lossos, @univmiami, discusses new agents in marginal zone #lymphoma such as ibrutinib, acalabrutinib, zanabrutinib, umbralisib, parsaclisib, and axi-cel. Upcoming trials at his institution include phase II studies of mosunetuzumab for ND EMZL and… pic.twitter.com/zwwzbM4FNQ
CONGRESS | #SOHO2024
— Lymphoma Hub (@lymphomahub) September 9, 2024
Jorge Castillo, @DanaFarber shared insights into management of Waldenström's macroglobulinaemia.
▪️ 80% of patients will need treatment
▪️ Toxicities remain a problem in selecting treatments, which could be managed with dose reduction
▪️ Based on the ASPEN… pic.twitter.com/mKBBauQE0O
More about...
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Thank youYour opinion matters
60 votes - 50 days left ...
Related articles
Newsletter
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox